Lifestyle

Mezzion Pharma Co., Ltd. Overturns U.S. Patent Rejection… Completely Blocks ‘Generic’ Udenafil

KIM JI-WAN
2026-11-20 07:16:03
[Edaily Reporter KIM JI-WAN ] Mezzion Pharma Co., Ltd.(140410)has overturned a rejection decision that had been blocking the registration of a U.S. patent for the use of Udenafil in the treatment of liver disease. The company plans to add a new value proposition—the inhibition of liver fibrosis—to Udenafil, which is currently being developed to improve physical performance in patients who have undergone the Fontan procedure. The strategy is to establish long-term market competitiveness by confirming the drug’s therapeutic potential in clinical trials while simultaneously securing patents to protect it.

Mezzion Pharma Co., Ltd. website. (Screenshot byKIM JI-WAN reporter)


According to Mezion Pharma Co., Ltd. on the 16th, the U.S. Patent Trial and Appeal Board (PTAB) overturned the examiner’s rejection decision regarding the patent for the use of Udenafil in treating Fontan-associated liver disease (FALD). This marks a significant milestone in the company’s efforts to secure a U.S. patent, which it has been pursuing since 2021.
Seeking protection through 2042… Additional extension expected due to examination delays
Mezzion Pharma Co., Ltd. stated, “In its decision, the PTAB ruled that ‘there was a clear error in the examiner’s judgment’ regarding the examiner’s original grounds for rejection and issued a decision overturning the rejection in favor of the applicant.”

This decision overturns a rejection issued during the patent application examination process through an appeal hearing. Subsequent examination, a decision to grant the patent, and the payment of registration fees remain before the patent is finally issued.

A Mezion Pharma Co., Ltd. official explained, “If the examiner fully accepts the PTAB’s ruling, a notice of patent registration will be issued shortly,” adding, “The basic expiration date upon patent registration is August 12, 2042, and an additional extension of the patent term is expected to be granted due to the prolonged examination history.”

According to the U.S. Patent and Trademark Office (USPTO) examination guidelines, when an examiner’s rejection decision is overturned, subsequent procedures are initiated. Approval from the relevant supervisor is required to resume examination by applying new grounds for rejection to the overturned claims.

With this ruling by the Patent Trial and Appeal Board, the expansion of Udenafil’s patent portfolio for the treatment of fondan-associated liver disease will begin in earnest.

Mezzion Pharma Co., Ltd. stated, “We plan to vigorously pursue patent registration in major global markets such as Europe, Japan, and Australia.”
Strain
on the Liver Following Heart Surgery… Aiming to Expand Treatment Scope

Fontan-associated liver disease is a liver condition related to changes in blood circulation following Fontan surgery. Fontan surgery is a procedure that alters the circulatory pathway in patients with congenital heart disease—where one ventricle primarily functions—so that venous blood flows directly to the pulmonary artery without passing through the ventricle.

While the surgery improves survival rates, it does not create a circulatory system identical to that of a normal heart. Chronically elevated venous pressure and blood stasis place a burden on the liver. Over time, liver fibrosis progresses, and some patients may develop serious complications such as cirrhosis. This is why managing the long-term health of Fontan patients requires monitoring not only their exercise capacity and cardiac function but also the condition of their liver.

(Graphic: ChatGPT)


A Mezion Pharma Co., Ltd. representative stated, “The LF score, a marker of liver fibrosis, is already incorporated as a key secondary endpoint in the ongoing FUEL-2 clinical protocol.” He added, “This expands the development value of Udenafil from improving exercise capacity to the potential for inhibiting liver fibrosis and improving long-term prognosis.”

LF is a marker calculated by combining fibrosis-related substances in the blood. The study is designed to evaluate the effects on exercise capacity while simultaneously monitoring changes related to liver fibrosis.

Positive signs were observed in previous clinical trials. The FUEL FALD study, published this year in the international journal *Pediatric Cardiology*, analyzed liver stiffness and fibrosis-related blood markers in 88 Fontan patients before and after treatment with udenafil. In that study, the average LF score decreased from 10.4 before treatment to 9.8 after 12 months. This was a statistically significant change (p<0.0001).

70,000 Patients Worldwide; Patent Value Lies in ‘Sales Protection’
The global population of Fontan patients exceeds 70,000. Nevertheless, there is no established drug therapy that directly prevents or treats Fontan-associated liver disease. Johnson & Johnson (J&J), a global pharmaceutical company, also attempted to improve exercise capacity in Fontan patients with its pulmonary arterial hypertension treatment “Opsumit” (active ingredient: masitenan), but failed to demonstrate efficacy in clinical trials.

During an investor briefing last December, Mezion Pharma Co., Ltd. presented an estimated annual treatment cost of $180,000 for Udenafil in the U.S. Applying this figure, if 1,000 patients in the U.S. receive treatment for one year, annual sales would amount to $180 million; for 5,000 patients, it would be $900 million. Using an exchange rate of 1,400 won per dollar for these calculations, the figures would be 252 billion won and 1.26 trillion won, respectively. Of course, these are not confirmed drug prices. This is a simple scenario that does not account for factors such as insurance discounts or differences between invoiced and actual amounts received.

However, the economic benefits of this patent are clear. It is not about Udenafil’s total sales, but rather how much of the revenue loss that would occur without the patent can be prevented. For example, in the 1,000-patient prescription scenario, annual sales would decrease by 30% due to the entry of competing drugs; assuming this patent fully protects against that loss, the annual protective effect amounts to $54 million, or approximately 75.6 billion won.

Mezzion Pharma Co., Ltd. emphasized, “Due to their structural hemodynamic characteristics, patients who have undergone the Fontan procedure inevitably face complications such as liver fibrosis and cirrhosis,” adding, “By securing differentiated rights for FALD treatment, we are effectively blocking the market entry of low-cost generic drugs and providing frontline medical professionals with strong clinical and academic grounds to prioritize prescribing Udenafil as the first-line standard treatment for Fontan patients.”

The representative further noted that “following approval by the U.S. Food and Drug Administration (FDA), we will secure an overwhelming advantage in cost-effectiveness evaluations during insurance listing and drug pricing negotiations.”

Economy

Corporation

IT·Science

Economy

BlackRock: "Tokenization Offers Greater Growth Opportunities Than Virtual Asset ETFs"

BlackRock, the world’s largest asset manager, forecasts additional growth opportunities in the Bitcoin and cryptocurrency investment product markets. However, the firm predicts that tokenization will …
2026-11-20 07:31:12

IT·Science

“They Stay Put Even When You Run”… Samsung to Release Sports Earbuds [Morning Phone]

It appears that SamsungElectronics(005930)is preparing to launch the “Galaxy Buds Active,” wireless earbuds designed to stay securely in place even during exercise. The earbuds feature a hook-style de…
2026-11-20 07:17:54